RMD Stock Down -7.7% after 6-Day Loss Streak
ResMed (RMD) stock hit day 6 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -7.7% return. The company has lost about $3.1 Bil in value over the last 6 days, with its current market capitalization at about $40 Bil. The stock remains 19.3% above its value at the end of 2024. This compares with year-to-date returns of 9.1% for the S&P 500.
RMD provides medical devices and cloud-based software for healthcare, including remote monitoring and personalized therapy management applications for sleep apnea patients. Is this drop a warning sign or a setup for rebound? Deep dive with Buy or Sell RMD.
Comparing RMD Stock Returns With The S&P 500
The following table summarizes the return for RMD stock vs. the S&P 500 index over different periods, including the current streak:
- Stocks, Bonds, Gold, Crypto: Market Update 12/22/2025
- Would You Still Hold Dillard’s Stock If It Fell Another 30%?
- With Trump Media & Technology Stock Sliding, Have You Assessed The Risk?
- Is Seagate Technology Stock Built to Withstand a Pullback?
- With Carnival Stock Surging, Have You Considered The Downside?
- Tilray Brands Stock Tumbled 25% – Opportunity or Trap?
| Return Period | RMD | S&P 500 |
|---|---|---|
| 1D | -1.3% | -0.7% |
| 6D (Current Streak) | -7.7% | -0.8% |
| 1M (21D) | -2.7% | 2.8% |
| 3M (63D) | 11.3% | 8.1% |
| YTD 2025 | 19.3% | 9.1% |
| 2024 | 34.2% | 23.3% |
| 2023 | -16.5% | 24.2% |
| 2022 | -19.5% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: RMD Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 36 S&P constituents with 3 days or more of consecutive gains and 93 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 14 | 62 |
| 4D | 13 | 13 |
| 5D | 5 | 3 |
| 6D | 0 | 15 |
| 7D or more | 4 | 0 |
| Total >=3 D | 36 | 93 |
Key Financials for ResMed (RMD)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $4.7 Bil | $5.1 Bil |
| Operating Income | $1.4 Bil | $1.7 Bil |
| Net Income | $1.0 Bil | $1.4 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ3 | 2025 FQ4 |
|---|---|---|
| Revenues | $1.3 Bil | $1.3 Bil |
| Operating Income | $426.3 Mil | $456.6 Mil |
| Net Income | $365.0 Mil | $379.7 Mil |
The losing streak RMD stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.